文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

免疫功能低下急性呼吸衰竭成人中PCR与β-D-葡聚糖诊断耶氏肺孢子菌肺炎的结果解读

Interpretation of results of PCR and B-D-glucan for the diagnosis of Pneumocystis Jirovecii Pneumonia in immunocompromised adults with acute respiratory failure.
PubMed 文献 · Ann Intensive Care · 2024-07-31
一句话结论在非HIV免疫功能低下急性呼吸衰竭患者中PJP发生率仅4.1%,PCR和BDG阳性后验概率分别仅32.9%和22.8%,阴性后验概率极低(0.10%和0.23%)。

该研究从文献提取PCR和BDG的诊断性能,在2243例非HIV免疫功能低下急性呼吸衰竭患者数据集中评估肺孢子菌肺炎(PJP)发生率,并用贝叶斯定理计算后验概率。PJP总发生率为4.1%(95%CI 3.3-5);监督分类识别出4个亚组,发生率从2.0%(无磨玻璃影;95%CI 1.4-2.8)到20.2%(造血细胞移植、磨玻璃影且无PJP预防;95%CI 14.1-27.7)。总体人群PCR和BDG阳性后验概率分别为32.9%(95%CI 31.1-34.8)和22.8%(95%CI 21.5-24.3),阴性后验概率分别为0.10%(95%CI 0.09-0.11)和0.23%(95%CI 0.21-0.25)。最高风险亚组中PCR和BDG阳性预测值分别为74.5%(95%CI 72.0-76.7)和63.8%(95%CI 60.8-65.8)。作者提出一种展示验前与验后概率关系的方法,可能改善临床医生对诊断试验性能随疾病发生率变化的认识。

要点

  • 非HIV免疫功能低下急性呼吸衰竭患者PJP发生率为4.1%(95%CI 3.3-5),总体阳性后验概率PCR 32.9%(95%CI 31.1-34.8)、BDG 22.8%(95%CI 21.5-24.3)。
  • 总体人群阴性后验概率极低:PCR 0.10%(95%CI 0.09-0.11)、BDG 0.23%(95%CI 0.21-0.25),阴性结果对排除PJP价值高。
  • 最高风险亚组(造血细胞移植、磨玻璃影且无PJP预防)发生率20.2%(95%CI 14.1-27.7),阳性预测值PCR 74.5%(95%CI 72.0-76.7)、BDG 63.8%(95%CI 60.8-65.8)。
  • 最低风险亚组(无磨玻璃影)发生率2.0%(95%CI 1.4-2.8),阳性后验概率相应更低。
  • 作者提出用验前-验后概率关系图辅助临床医生根据疾病发生率解读PCR和BDG结果。

适用人群与场景

  • 非HIV免疫功能低下成人急性呼吸衰竭患者,数据来自2243例患者数据集。
  • 监督分类识别出4个亚组,包括无磨玻璃影者(发生率2.0%,95%CI 1.4-2.8)和造血细胞移植、磨玻璃影且无PJP预防者(发生率20.2%,95%CI 14.1-27.7)。

研究设计与关键结果

  • 研究类型:诊断性能研究,从文献提取PCR和BDG诊断性能,在2243例非HIV免疫功能低下急性呼吸衰竭患者中评估PJP发生率,并用贝叶斯定理计算后验概率。
  • PJP总发生率4.1%(95%CI 3.3-5);监督分类识别4个亚组,发生率从2.0%(无磨玻璃影;95%CI 1.4-2.8)到20.2%(造血细胞移植、磨玻璃影且无PJP预防;95%CI 14.1-27.7)。
  • 总体人群阳性后验概率:PCR 32.9%(95%CI 31.1-34.8),BDG 22.8%(95%CI 21.5-24.3)。
  • 总体人群阴性后验概率:PCR 0.10%(95%CI 0.09-0.11),BDG 0.23%(95%CI 0.21-0.25)。
  • 最高风险亚组阳性预测值:PCR 74.5%(95%CI 72.0-76.7),BDG 63.8%(95%CI 60.8-65.8)。

证据类型、等级与局限

  • 证据类型:基于文献提取诊断性能并结合临床数据集的诊断准确性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,尽管PCR和BDG固有性能高,但PJP在非HIV免疫功能低下急性呼吸衰竭患者中发生率低,导致阳性后验概率低,临床解读阳性结果时需结合验前概率。
  • 作者提出一种展示验前与验后概率关系的方法,可能改善临床医生对诊断试验性能随疾病发生率变化的认识。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The accuracy of a diagnostic test depends on its intrinsic characteristics and the disease incidence. This study aims to depict post-test probability of Pneumocystis pneumonia (PJP), according to results of PCR and Beta-D-Glucan (BDG) tests in patients with acute respiratory failure (ARF).

MATERIALS AND METHODS: Diagnostic performance of PCR and BDG was extracted from literature. Incidence of Pneumocystis pneumonia was assessed in a dataset of 2243 non-HIV immunocompromised patients with ARF. Incidence of Pneumocystis pneumonia was simulated assuming a normal distribution in 5000 random incidence samples. Post-test probability was assessed using Bayes theorem.

RESULTS: Incidence of PJP in non-HIV ARF patients was 4.1% (95%CI 3.3-5). Supervised classification identified 4 subgroups of interest with incidence ranging from 2.0% (No ground glass opacities; 95%CI 1.4-2.8) to 20.2% (hematopoietic cell transplantation, ground glass opacities and no PJP prophylaxis; 95%CI 14.1-27.7). In the overall population, positive post-test probability was 32.9% (95%CI 31.1-34.8) and 22.8% (95%CI 21.5-24.3) for PCR and BDG, respectively. Negative post-test probability of being infected was 0.10% (95%CI 0.09-0.11) and 0.23% (95%CI 0.21-0.25) for PCR and BDG, respectively. In the highest risk subgroup, positive predictive value was 74.5% (95%CI 72.0-76.7) and 63.8% (95%CI 60.8-65.8) for PCR and BDG, respectively.

CONCLUSION: Although both tests yield a high intrinsic performance, the low incidence of PJP in this cohort resulted in a low positive post-test probability. We propose a method to illustrate pre and post-test probability relationship that may improve clinician perception of diagnostic test performance according to disease incidence in predefined clinical settings.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Calvet L, Lemiale V, Mokart D, et al. Interpretation of results of PCR and B-D-glucan for the diagnosis of Pneumocystis Jirovecii Pneumonia in immunocompromised adults with acute respiratory failure. Ann Intensive Care. 2024. PMID: 39083132. doi:10.1186/s13613-024-01337-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。